UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 45.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 318,420 shares of the company's stock after purchasing an additional 99,866 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.10% of Amneal Pharmaceuticals worth $2,522,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Barclays PLC raised its position in Amneal Pharmaceuticals by 134.1% in the third quarter. Barclays PLC now owns 296,384 shares of the company's stock valued at $2,466,000 after purchasing an additional 169,756 shares during the period. Janney Montgomery Scott LLC acquired a new stake in shares of Amneal Pharmaceuticals in the fourth quarter valued at $121,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Amneal Pharmaceuticals in the 4th quarter valued at $81,000. Entropy Technologies LP acquired a new position in Amneal Pharmaceuticals during the 4th quarter worth about $259,000. Finally, Stonebridge Financial Group LLC purchased a new position in Amneal Pharmaceuticals during the 4th quarter valued at about $286,000. 31.82% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have issued reports on the stock. Wall Street Zen lowered shares of Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, May 13th. The Goldman Sachs Group started coverage on shares of Amneal Pharmaceuticals in a research note on Friday. They set a "buy" rating and a $12.00 target price on the stock. Barclays raised their price target on shares of Amneal Pharmaceuticals from $10.00 to $11.00 and gave the company an "overweight" rating in a research report on Monday, March 3rd. Finally, JPMorgan Chase & Co. raised Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and upped their price objective for the stock from $9.00 to $12.00 in a research report on Monday, February 24th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of "Buy" and a consensus price target of $11.60.

Insider Buying and Selling

In other news, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the firm's stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $8.35, for a total transaction of $41,750,000.00. Following the sale, the insider now owns 48,578,209 shares of the company's stock, valued at approximately $405,628,045.15. This trade represents a 9.33% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 26.56% of the company's stock.

Amneal Pharmaceuticals Price Performance

Shares of Amneal Pharmaceuticals stock traded up $0.20 on Tuesday, reaching $7.81. 2,298,701 shares of the company were exchanged, compared to its average volume of 1,456,347. The stock's 50 day moving average price is $7.37 and its 200-day moving average price is $7.95. Amneal Pharmaceuticals, Inc. has a 1-year low of $6.29 and a 1-year high of $9.48. The company has a market cap of $2.45 billion, a P/E ratio of -11.49 and a beta of 1.05.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last posted its quarterly earnings results on Friday, May 2nd. The company reported $0.19 EPS for the quarter, topping the consensus estimate of $0.14 by $0.05. Amneal Pharmaceuticals had a negative net margin of 6.88% and a negative return on equity of 346.26%. The company had revenue of $695.42 million during the quarter, compared to analysts' expectations of $714.78 million. On average, research analysts predict that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current fiscal year.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.